All Stories

  1. H3F3A K36M-mutant Epithelioid Neoplasm: A Report of Two Novel Cases of a Non-chondrogenic H3K36-altered Mesenchymal Tumor

    Article • Pediatric and Developmental Pathology, July 2025, SAGE Publications

    Dr Amos Loh

  2. Surgical Practices in the Management of Pediatric Renal Tumors in Low‐ and Middle‐Income Countries in the Asia Pacific Region

    Article • Pediatric Blood & Cancer, March 2025, Wiley

    Dr Amos Loh

  3. Introduction

    Article • January 2025, Springer Science + Business Media

    Dr Amos Loh

  4. Skeletal Muscle Tumours

    Article • January 2025, Springer Science + Business Media

    Dr Amos Loh

  5. Desmoplastic Small Round Cell Tumour

    Article • January 2025, Springer Science + Business Media

    Dr Amos Loh

  6. Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor

    Article • Cancers, September 2024, MDPI AG

    Dr Amos Loh

  7. Childhood cancer surgery in low‐ and middle‐income countries

    Article • Pediatric Blood & Cancer, August 2024, Wiley

    Dr Amos Loh

  8. Abstract P61: Distinct Roles of BRD4 Isoforms in Tumor Progression and Metastasis in Embryonal Rhabdomyosarcoma

    Article • Cancer Research, April 2024, American Association for Cancer Research (AACR)

    Dr Amos Loh

  9. Systematic Lymphatic Repair for Reduction of Postoperative Lymphatic Leak Following Neuroblastoma Resection

    Article • Journal of Pediatric Surgery, February 2024, Elsevier

    Dr Amos Loh

  10. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma

    Article • EMBO Reports, January 2024, Springer Science + Business Media

    Dr Amos Loh

  11. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  12. Data from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  13. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  14. FIGURE 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  15. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  16. FIGURE 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  17. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  18. FIGURE 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  19. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  20. FIGURE 4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  21. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  22. FIGURE 5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  23. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  24. Figure S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  25. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  26. Figure S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  27. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  28. Figure S3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  29. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  30. Figure S4 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  31. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  32. Figure S5 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  33. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  34. Figure S6 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  35. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  36. Figure S7 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  37. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  38. Supplementary Data - raw Western blot images from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  39. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  40. Supplementary Data 1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  41. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  42. Supplementary Data 2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  43. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  44. Supplementary Data 3 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  45. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  46. Supplementary Methods from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  47. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  48. Table S1 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  49. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  50. Table S2 from Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma

    Article • November 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  51. Targeted degradation of XIAP is sufficient and specific to induce apoptosis in MYCN-overexpressing high-risk neuroblastoma

    Article • Cancer Research Communications, October 2023, American Association for Cancer Research (AACR)

    Dr Amos Loh

  52. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody

    Article • Molecular Therapy — Oncolytics, September 2023, Elsevier

    Dr Amos Loh

  53. Solitary pulmonary nodule in an early adolescent

    Article • BMJ Case Reports, September 2023, BMJ

    Dr Amos Loh

  54. #299 Alveolar soft part sarcoma of the cervix mimicking a cervical fibroid: a diagnostic and management challenge

    Article • September 2023, BMJ

    Dr Amos Loh

  55. BRD4 isoforms have distinct roles in tumor progression and metastasis in embryonal rhabdomyosarcoma

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Dr Amos Loh

  56. Aggressive Pursuit of No Evidence of Disease Status in Hepatoblastoma Improves Survival: An Observational Study

    Article • Journal of Pediatric Surgery, June 2023, Elsevier

    Dr Amos Loh

  57. Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies

    Article • Biomedicines, April 2023, MDPI AG

    Dr Amos Loh

  58. Implementation of Multidisciplinary Teams for the Treatment of Childhood Cancer

    Article • January 2023, Springer Science + Business Media

    Dr Amos Loh

  59. Mitochondrial calcium uptake regulates tumour progression in embryonal rhabdomyosarcoma

    Article • Cell Death and Disease, April 2022, Springer Science + Business Media

    Dr Amos Loh

  60. Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study

    Article • Pediatric Blood & Cancer, January 2022, Wiley

    Dr Amos Loh

  61. Postoperative Rather Than Preoperative Neutropenia Is Associated With Early Catheter-related Bloodstream Infections in Newly Diagnosed Pediatric Cancer Patients

    Article • The Pediatric Infectious Disease Journal, January 2022, Wolters Kluwer Health

    Dr Amos Loh

  62. Subcutaneous panniculitis‐like T‐cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees

    Article • Pediatric Blood & Cancer, August 2021, Wiley

    Dr Amos Loh

  63. Gastrointestinal and oncologic outcomes of pediatric gastrointestinal lymphoma following upfront resection or biopsy of bowel masses

    Article • Pediatric Surgery International, May 2021, Springer Science + Business Media

    Dr Amos Loh

  64. Rhabdomyosarcoma

    Article • January 2021, Springer Science + Business Media

    Dr Amos Loh

  65. Pediatric Solid Tumor Care and Multidisciplinary Tumor Boards in Low- and Middle-Income Countries in Southeast Asia

    Article • JCO Global Oncology, September 2020, American Society of Clinical Oncology (ASCO)

    Dr Amos Loh

  66. Neuroblastoma patient‐derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response

    Article • Cancer Science, August 2020, Wiley

    Dr Amos Loh

  67. Massively parallel single-molecule telomere length measurement with digital real-time PCR

    Article • Science Advances, August 2020, American Association for the Advancement of Science

    Dr Amos Loh

  68. Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma

    Article • Journal of Oncology Pharmacy Practice, July 2020, SAGE Publications

    Dr Amos Loh

  69. Rhabdomyosarcoma

    Article • January 2020, Springer Science + Business Media

    Dr Amos Loh

  70. Posterior retroperitoneoscopic adrenalectomy for pediatric adrenal tumors

    Article • Journal of Pediatric Surgery, November 2019, Elsevier

    Dr Amos Loh

  71. Destined to Die: Apoptosis and Pediatric Cancers

    Article • Cancers, October 2019, MDPI AG

    Dr Amos Loh

  72. Retroperitoneal tumors and congenital variations in vascular anatomy of retroperitoneal great vessels

    Article • Journal of Pediatric Surgery, October 2019, Elsevier

    Dr Amos Loh

  73. Evaluation of a Novel Bony Landmark-Based Method for Teaching Percutaneous Insertion of Subclavian Venous Catheters in Pediatric Patients

    Article • Extremophiles, April 2019, Springer Science + Business Media

    Dr Amos Loh

  74. Primary Adrenal Angiomatoid Fibrous Histiocytoma With Novel EWSR1-ATF1 Gene Fusion Exon–Exon Breakpoint

    Article • Pediatric and Developmental Pathology, March 2019, SAGE Publications

    Dr Amos Loh

  75. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations

    Article • Cancer Letters, February 2019, Elsevier

    Dr Amos Loh

  76. Soft Tissue Sarcomas

    Article • January 2019, Springer Science + Business Media

    Dr Amos Loh

  77. Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children

    Article • International Journal of Cancer, December 2018, Wiley

    Dr Amos Loh

  78. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours

    Article • npj Genomic Medicine, November 2018, Springer Science + Business Media

    Dr Amos Loh

  79. Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion

    Article • Histopathology, October 2017, Wiley

    Dr Amos Loh

  80. Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing

    Article • Molecular Genetics & Genomic Medicine, July 2017, Wiley

    Dr Amos Loh

  81. Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients

    Article • Journal of Laparoendoscopic & Advanced Surgical Techniques, February 2017, Mary Ann Liebert Inc

    Dr Amos Loh

  82. Management of a Kaposiform haemangioendothelioma of the kidney with Kasabach-Meritt phenomenon without chemotherapy

    Article • Pediatric Hematology Oncology Journal, October 2016, Elsevier

    Dr Amos Loh

  83. Re: External validation of the Paediatric Risk of Malignancy Index

    Article • BJOG An International Journal of Obstetrics & Gynaecology, June 2016, Wiley

    Dr Amos Loh

  84. Initial diagnostic management of pediatric bone tumors

    Article • Journal of Pediatric Surgery, June 2016, Elsevier

    Dr Amos Loh

  85. XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis

    Article • Oncotarget, April 2016, Impact Journals, LLC

    Dr Amos Loh

  86. Thyroglossal duct cyst carcinoma: diagnostic and management considerations in a 15-year-old with a large submental mass

    Article • BMJ Case Reports, July 2015, BMJ

    Dr Amos Loh

  87. Novel Karyotypes and Cyclin D1 Immunoreactivity in Clear Cell Sarcoma of the Kidney

    Article • Pediatric and Developmental Pathology, July 2015, SAGE Publications

    Dr Amos Loh

  88. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

    Article • Clinical Cancer Research, April 2015, American Association for Cancer Research (AACR)

    Dr Amos Loh

  89. Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors

    Article • Journal of Pediatric Surgery, April 2015, Elsevier

    Dr Amos Loh

  90. Safety and diagnostic accuracy of tumor biopsies in children with cancer

    Article • Cancer, December 2014, Wiley

    Dr Amos Loh

  91. An Approach to Renal Masses in Pediatrics

    Article • PEDIATRICS, December 2014, American Academy of Pediatrics (AAP)

    Dr Amos Loh

  92. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma

    Article • Pediatric Blood & Cancer, November 2014, Wiley

    Dr Amos Loh

  93. Targeting the DNA Repair Pathway in Ewing Sarcoma

    Article • Cell Reports, November 2014, Elsevier

    Dr Claudia A Benavente, Dr Amos Loh

  94. The Role of Thoracoscopic Surgery in Pediatric Oncology

    Article • Journal of Laparoendoscopic & Advanced Surgical Techniques, November 2014, Mary Ann Liebert Inc

    Dr Amos Loh

  95. Minimally invasive surgery in the management of abdominal tumors in children

    Article • Journal of Pediatric Surgery, July 2014, Elsevier

    Dr Amos Loh

  96. Management of Local Recurrence of Pediatric Osteosarcoma Following Limb-Sparing Surgery

    Article • Annals of Surgical Oncology, February 2014, Springer Science + Business Media

    Dr Amos Loh

  97. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?

    Article • Pediatric Surgery International, May 2013, Springer Science + Business Media

    Dr Amos Loh

  98. Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration

    Article • Frontiers in Oncology, January 2013, Frontiers

    Dr Amos Loh

  99. Pediatric risk of malignancy index for preoperative evaluation of childhood ovarian tumors

    Article • Pediatric Surgery International, December 2011, Springer Science + Business Media

    Dr Amos Loh

  100. Diagnostic delay in pediatric solid tumors: A population based study on determinants and impact on outcomes

    Article • Pediatric Blood & Cancer, November 2011, Wiley

    Dr Amos Loh

  101. Corrigenda

    Article • Pediatric Hematology and Oncology, August 2011, Taylor & Francis

    Dr Amos Loh

  102. Gene Expression of TRK Neurotrophin Receptors in Advanced Neuroblastomas in Singapore—A Pilot Study

    Article • Pediatric Hematology and Oncology, July 2011, Taylor & Francis

    Dr Amos Loh

  103. Neonatal Ovarian Cysts: Role of Sonography in Diagnosing Torsion

    Article • Annals of the Academy of Medicine Singapore, June 2011, Academy of Medicine, Singapore

    Dr Amos Loh

  104. Delays in Diagnosis of Pediatric Solid Tumors in Singapore

    Article • Journal of Pediatric Hematology/Oncology, October 2009, Wolters Kluwer Health

    Dr Amos Loh

  105. Port-A-Cath insertions in acute leukemia: does thrombocytopenia affect morbidity?

    Article • Journal of Pediatric Surgery, July 2007, Elsevier

    Dr Amos Loh

  106. Port-A-Cath Insertions in Acute Leukaemia and Childhood Malignancies

    Article • Asian Journal of Surgery, July 2007, Elsevier

    Dr Amos Loh

  107. Neonatal intestinal volvulus due to a persistent right vitelline artery

    Article • Pediatric Surgery International, October 2006, Springer Science + Business Media

    Dr Amos Loh